Dual Therapy with Raltegravir Plus a Fixed Dose Combination of Darunavir/ritonavir in People Living with HIV in Argentina

Overview

Journal Rev Esp Quimioter

Specialty Pharmacology

Date 2020 Dec 3

PMID 33267555

Authors

F Rombini

D M Cecchini

J Ballivian

M Huberman

A Uruena

I Cassetti

Affiliations

Soon will be listed here.

Abstract

Objective: There are generic fixed-dose combinations (FDCs) of ritonavir-boosted darunavir (DRV/r) available in Argentina. Experiences with these FDCs in dual therapy remain limited in clinical practice. We aimed to describe clinical and virologic outcomes in patients exposed to FDC DRV/r + raltegravir (RAL) 400 mg every 12 h in a real-life setting.

Methods: Retrospective analysis of electronic medical records of HIV-infected patients under FDC DRV/r + RAL in an HIV clinic in Argentina (2014-2018). Individuals were classified as "switch group" (SG, undetectable viral load [VL] with any toxicity/comorbidity) and "virologic group· (VG, detectable viremia and infection by multidrug-resistant HIV).

Results: Of 7,380 patients on ART, 116 (1.5%) received FDC DRV/r + RAL, being 58% in SG. Sixty percent received DRV/r 800/100 mg dose (rest, 600/100 mg). The median (IQR) age and CD4+ T-cell count were: 52 (42-58) years, and 373 cell/µL (202-642). Ninety-eight percent were ART-experienced with a median of 3 (IQR 2-5) prior treatments. Main reasons for switch (SG) were renal (57%), cardiovascular (54%) and bone (14%) comorbidities. Median exposure to DRV/r + RAL was 18 months. Among patients in SG, 98% and 96% had undetectable VL at 6 and 12 months; in the VG, 89% and 87% had undetectable VL at 6 and 12 months. No patient required suspension due to toxicity/ intolerance.

Conclusions: In this cohort of mostly experienced HIV-infected patients, FDC DRV/r + RAL was effective and safe. Such therapy may be considered an option for patients with comorbid conditions and/or with multidrug-resistant HIV.

References

Jablonowska E, Pulik P, Kalinowska A, Gasiorowski J, Parczewski M, Bociaga-Jasik M . Dual therapy based on raltegravir and boosted protease inhibitors - the experience of Polish centers. Arch Med Sci. 2018; 14(4):860-864. PMC: 6040130. DOI: 10.5114/aoms.2016.62445. View

Margolis A, Heverling H, Pham P, Stolbach A . A review of the toxicity of HIV medications. J Med Toxicol. 2013; 10(1):26-39. PMC: 3951641. DOI: 10.1007/s13181-013-0325-8. View

Mesplede T, Wainberg M . Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence. Viruses. 2015; 7(7):3703-18. PMC: 4517119. DOI: 10.3390/v7072790. View

Soriano V, Fernandez-Montero J, Benitez-Gutierrez L, de Mendoza C, Arias A, Barreiro P . Dual antiretroviral therapy for HIV infection. Expert Opin Drug Saf. 2017; 16(8):923-932. DOI: 10.1080/14740338.2017.1343300. View

Quashie P, Mesplede T, Wainberg M . HIV Drug Resistance and the Advent of Integrase Inhibitors. Curr Infect Dis Rep. 2012; 15(1):85-100. DOI: 10.1007/s11908-012-0305-1. View

Madeddu G, Rusconi S, Cozzi-Lepri A, Di Giambenedetto S, Bonora S, Carbone A . Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL. Infection. 2017; 45(4):521-528. DOI: 10.1007/s15010-017-1018-z. View

Smith C, Ryom L, Weber R, Morlat P, Pradier C, Reiss P . Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet. 2014; 384(9939):241-8. DOI: 10.1016/S0140-6736(14)60604-8. View

Schouten J, Wit F, Stolte I, Kootstra N, Van Der Valk M, Geerlings S . Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis. 2014; 59(12):1787-97. DOI: 10.1093/cid/ciu701. View

Guaraldi G, Milic J, Mussini C . Aging with HIV. Curr HIV/AIDS Rep. 2019; 16(6):475-481. DOI: 10.1007/s11904-019-00464-3. View

10.

Baril J, Angel J, Gill M, Gathe J, Cahn P, van Wyk J . Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients. PLoS One. 2016; 11(2):e0148231. PMC: 4746196. DOI: 10.1371/journal.pone.0148231. View

11.

Christensen S, Wolf E, Altevers J, Diaz-Cuervo H . Comorbidities and costs in HIV patients: A retrospective claims database analysis in Germany. PLoS One. 2019; 14(11):e0224279. PMC: 6834270. DOI: 10.1371/journal.pone.0224279. View

12.

Nishijima T, Gatanaga H, Shimbo T, Komatsu H, Endo T, Horiba M . Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trial. PLoS One. 2013; 8(8):e73639. PMC: 3738570. DOI: 10.1371/journal.pone.0073639. View

13.

de Miguel R, Montejano R, Stella-Ascariz N, Arribas J . A safety evaluation of raltegravir for the treatment of HIV. Expert Opin Drug Saf. 2017; 17(2):217-223. DOI: 10.1080/14740338.2018.1411903. View

14.

Jablonowska E, Pulik P, Kalinowska A, Gasiorowski J, Parczewski M, Bociaga-Jasik M . Efficacy and safety of nucleoside-sparing regimen based on raltegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients. J Med Virol. 2017; 89(12):2122-2129. DOI: 10.1002/jmv.24826. View